DOI: https://dx.doi.org/10.18203/2320-6012.ijrms20222266
Published: 2022-08-29

Clinicopathological features and prognostic factors in endometrial carcinoma: a retrospective analysis from a tertiary cancer centre

Veerendra Angadi, Esther Praisy, Tushar Tatineni, Shashidhar V. Karpurmath, Manjunath I. Nandennavar

Abstract


Background: Endometrial carcinoma (EC) is most common gynecological malignancy. The incidence of endometrial cancer is rising rapidly with only limited evidence on the clinicopathological features, survival data and prognostic factors. The study aimed to evaluate the clinicopathological features, treatment, recurrence pattern, survival and to assess the prognostic factors in patients with endometrial carcinoma.

Methods: After obtaining approval from institutional ethics committee, 94 patients who were diagnosed with EC were included in the study. The data were presented as proportions and survival curve analysis was done using the Kaplan Meir curve and significance using log rank tests.

Results: A total of 94 patients diagnosed with EC were included in the study with a mean age of 55.1 years. The Myometrial invasion was observed in 46.9% of the patients with 35.2% having lymphovascular involvement. Clinical characteristics of the patients showed grade 1 (35.1%) followed by grade III (17.02%). Survival analysis showed that elderly age, multi parity, advanced disease stage, more than 50% of myometrial invasion, grade II and grade III tumors, lymphovascular space invasion, adversely affected long‑term survival when analyzed by log-rank test. The disease-free survival (DFS) at 5 years was found to be 77% and overall survival (OS) at 5 years was 79.7%.

Conclusions: Endometrial carcinoma is seen commonly in postmenopausal women wherein delaying the treatment significantly affects the long‑term survival. Therefore, early diagnosis reduces the mortality and increases the disease-free survival in these patients.


Keywords


Endometrial carcinoma, Myometrial invasion, Postmenopausal

Full Text:

PDF

References


Thomas V, Thomas A, Sebastian A, Chandy R, Peedicayil A. Inadequately staged endometrial cancer: a clinical dilemma. Indian J Surg Oncol. 2018;9(2):166-70.

Southcott BM. Carcinoma of the endometrium. Drugs. 2001;61(10):1395-405.

Singh P, Ray C, Mandal R. Experience with women having uterine cancer in Eastern India: a hospital based study. Int J Reprod Contracept Obstet Gynecol. 2020;9.

Signorelli M, Lissoni AA, De Ponti E, Grassi T, Panti S, Fruscio R. Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancer. J Gynecol Oncol. 2015;26(4):284-92.

Gottwald L, Pluta P, Piekarski J, Spych M, Hendzel K, Topczewska-Tylinska K, et al. Long-term survival of endometrioid endometrial cancer patients. Arch Med Sci. 2010;6(6):937-44.

Lewin SN. Revised FIGO staging system for endometrial cancer. Clin Obstet Gynecol. 2011;54(2):215-8.

Sartori E, Laface B, Gadducci A, et al. Factors influencing survival in endometrial cancer relapsing patients: a Cooperation Task Force (CTF) study. Int J Gynecol Cancer. 2003;13:458-6.

Andleeb A, Fatima K, Nasreen S, Sofi MA, Qadri SK. Endometrial carcinoma: A single institute experience. J Rad Cancer Res. 2021;2(3):119-25.

Elissawy FM, Halim AAF, Abdel-Latif RM, Nour-Elden AM, Hasaan A et al.; Asian oncology research journal 3(2):2020;7-27.

Boronow RC, Morrow CP, Creasman WT, Disaia P, Silverberg SG, Miller A, Blessing JA. Surgical staging in endometrial cancer: Clinical-pathologic findings of a prospective study. Obstet Gynecol. 1984;63:825-32.